Pfizer has reported the top-line results of a prospective Phase III, double-blind clinical trial which compared the combination of Vfend (voriconazole) and Eraxis (anidulafungin) to Vfend monotherapy for primary therapy of invasive aspergillosis (IA).
The Phase III study enrolled a total of 454 patients and was intended to compare mortality rates at six weeks after initiation of study treatment in patients with a diagnosis of proven or probable IA.
Go deeper with GlobalData
In the primary analysis, treatment with the combination of Vfend and Eraxis resulted in a lower all-cause mortality rate at six weeks compared to Vfend alone, but the safety and tolerability of the combination of Vfend and Eraxis was found similar to that of Vfend monotherapy.
Vfend IV/Oral is the only broad-spectrum IV/oral triazole antifungal medication specifically indicated for the first-line treatment of both mould and yeast infections.
